E-cigarettes are 'still a $7 billion category' despite paused FDA ban on Juul: Analyst

Industry InsightMarket
Jul.11.2022
The e-cigarette industry is facing another crackdown even as the FDA has temporarily paused its ban on Juul sales.

The e-cigarette industry is facing another crackdown even as the FDA has temporarily paused its ban on Juul sales.

E-cigarettes are 'still a $7 billion category' despite paused FDA ban on Juul: Analyst

While the industry's latest battle with the FDA has been specific to Juul, it has faced ongoing scrutiny, particularly around teenage vaping. In 2020, for example, the FDA ordered e-cigarette makers to cease making unauthorized vape flavors. Juul proactively removed its signature mango and cucumber pods.

 

But regulatory action hasn't prevented the category from growing, according to one analyst.

 

“E-cigarettes [are] still a $7 billion category in the U.S.,” Vivien Azer, research analyst and managing director at Cowen, told Yahoo Finance (video above). "It's certainly had its challenges and took a dip when novel characterizing flavors were removed. ... The category is back in growth mode."

 

Altria Group (MO), which is the majority investor in Juul, has seen significant losses in recent weeks after the FDA banned sales of Juul products in U.S. over safety concerns. Juul immediately filed to appeal the FDA's decision, alleging that the agency overlooked 6,000 pages of data on the safety of aerosols within its vapes.

 

Altria invested $12.8 billion into Juul Labs for a 35% stake in December 2018, effectively putting "all their eggs in that basket,” Azer said. The agreement, which drew scrutiny from the FTC, included a noncompete clause that limited Altria's ability to pursue its own vape products.

 

“Now, the value of that stake has gone down to $1.6 billion as of the first quarter of 2022," she added, "so a very meaningful reduction, but it still doesn't release Altria from the non-compete. The value of that $12.8 billion Juul stake has to fall by 90% or more for Altria to take their own path on e-cigarettes.”

 

Although Altria hopes to reintroduce its iQOS heat-not-burn tobacco device to U.S. markets in 2024, the Marlboro maker has been slowed by patent disputes from competitors.

 

"The e-vapor category through convenience and gas stores is very tight from a competitive standpoint," Azer said. "So being able to move in as a disruptor is certainly going to be more costly to Altria than continuing to lean into that Juul investment."

 

Geoff Braithwaite, owner of Tasty Vapor, exhales vapor after using an electronic cigarette Wednesday, Jan. 28, 2015, in Oakland, Calif. California health officials on Wednesday declared electronic cigarettes a health threat that should be strictly regulated like tobacco products, joining other states and health advocates across the U.S. in seeking tighter controls as

Geoff Braithwaite, owner of Tasty Vapor, exhales vapor after using an electronic cigarette Wednesday, Jan. 28, 2015, in Oakland, Calif. (AP Photo/Ben Margot)

Other tobacco players like Philip Morris International (PM) have been faring better and have recouped losses since the beginning of the pandemic.

 

The MSCI World Tobacco Index shows that the tobacco industry drew returns of 15.07% in 2021. Philip Morris International controls $153 billion (40.39%) of the index fund's $379 billion market cap. Other brands on the index include Altria, Camel-distributor British American Tobacco (BTI), Swedish Match (SWMAY), Japan Tobacco, and Imperial Brands.

 

At the outset, the FDA's ban on Juul may appear to be a significant regulatory headwind for the industry as a whole, but Azer asserted that e-cigarette companies "expect the e-cigarette category to remain viable" as an alternative to smoking.

 

"The FDA is pursuing two strategies in cigarettes that suggest that they do want to move consumers down the risk continuum," she added.

 

Alongside the contested Juul ban, the FDA has proposed capping sales and production of cigarettes and cigars that are flavored and contain menthol. The American Medical Association has backed this move as well as the FDA's projections that a menthol ban could drop smoking activity by 15.1% within 40 years, saving 324,000 to 654,000 lives.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
SnowPlus has introduced a nicotine-free version of DASH in South Korea, adapting an existing overseas disposable platform for the local market. The Korean version retains the series’ flat duckbill-style mouthpiece, ceramic heating architecture and disposable form factor while reducing nicotine content to 0%. By comparison, the overseas DASH 4000 platform typically features 7.5ml of prefilled e-liquid, up to 4,000 puffs and a 530mAh rechargeable battery, with nicotine-containing variants available in some markets. The product update centers on formulation localisation rather than a new hardware generation.
Aug.31
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24